Filtered By:
Specialty: Cardiology
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 1170 results found since Jan 2013.

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
CONCLUSIONS: Low-dose NOACs were comparable to standard-dose NOACs considering risks of ischemic stroke, major bleeding, ICH, and GH, and they were superior to warfarin. Low-dose NOACs might be prescribed effectively and safely for patients with AF. Considering limitations, further well-designed prospective studies are foreseen.PMID:35449605 | PMC:PMC9017587 | DOI:10.1155/2022/4713826
Source: Cardiology Research and Practice - April 22, 2022 Category: Cardiology Authors: Ze Li Xiaozhen Wang Dandan Li Aiping Wen Source Type: research

Atrial Fibrillation in Heart Failure
This article explores the relationship between AF and HF and the thromboembolic effect of these diseases. Morbidity and mortality are increased when the 2 conditions are seen together. Stroke risks are significant with AF and all subtypes of HF. This article suggests that all patients with AF and HF should be considered for anticoagulation. Current evidence suggests that non –vitamin K antagonist oral anticoagulants are effective and safe in AF and HF in comparison with warfarin.
Source: Cardiology Clinics - April 22, 2022 Category: Cardiology Authors: Mohammed Obeidat, Malcolm Burgess, Gregory Y.H. Lip Source Type: research

A Study of Srum Homocysteine Level in Ischaemic Stoke
CONCLUSION: The present study revealed that hyperhomocysteinemia appears to be an important risk factor for ischemic stroke. It is therefore important to use serum homocysteine as an important tool to investigate all cases of ischemic stroke and if serum homocysteine is elevated patient should be put on multivitamins containing vitamin B12, folic acid and pyridoxine to reduce serum homocysteine levels.PMID:35443421
Source: Atherosclerosis - April 21, 2022 Category: Cardiology Authors: Kaushik Paul Ramakrishna Mr Source Type: research

Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society
ConclusionsSignificant progress has been made within the past 2 decades both in the pharmacological and non-pharmacological managements of this cardiac arrhythmia.
Source: Journal of Interventional Cardiac Electrophysiology - April 13, 2022 Category: Cardiology Source Type: research

The Controversial Role of HCY and Vitamin B Deficiency in Cardiovascular Diseases
Nutrients. 2022 Mar 28;14(7):1412. doi: 10.3390/nu14071412.ABSTRACTPlasma homocysteine (HCY) is an established risk factor for cardiovascular disease CVD and stroke. However, more than two decades of intensive research activities has failed to demonstrate that Hcy lowering through B-vitamin supplementation results in a reduction in CVD risk. Therefore, doubts about a causal involvement of hyperhomocysteinemia (HHcy) and B-vitamin deficiencies in atherosclerosis persist. Existing evidence indicates that HHcy increases oxidative stress, causes endoplasmatic reticulum (ER) stress, alters DNA methylation and, thus, modulates t...
Source: Atherosclerosis - April 12, 2022 Category: Cardiology Authors: Wolfgang Herrmann Markus Herrmann Source Type: research

Comparison of the Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants with Warfarin in Atrial Fibrillation Patients with a History of Bleeding: A Systematic Review and Meta-Analysis
ConclusionsNOACs showed better efficacy and safety profile compared with warfarin in patients with AF and a history of bleeding. Randomized controlled trials are warranted to validate these findings.
Source: American Journal of Cardiovascular Drugs - March 16, 2022 Category: Cardiology Source Type: research

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
ConclusionsDabigatran was associated with a 39% reduced risk of major bleeding and 22% reduced risk for all-cause death compared with VKA. Stroke and myocardial infarction risks were similar, confirming a more favorable benefit-risk profile for dabigatran compared with VKA in clinical practice.Clinical trial registrationhttps://www.clinicaltrials.gov. NCT01468701, NCT01671007.Graphical abstract
Source: Clinical Research in Cardiology - March 16, 2022 Category: Cardiology Source Type: research

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
ConclusionsPatients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death.RegistrationURL:https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013.Graphical abstract
Source: Clinical Research in Cardiology - March 16, 2022 Category: Cardiology Source Type: research